Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$84.72MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven L. Basta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 0.50
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.88
Financials
Revenue
$84.72M+12322.6%Net Income
$-13.90MEBITDA
$1.61MFree Cash Flow
$1.73MEPS (diluted)
$-0.16Shares Outstanding (diluted)
84.89M+1492.4%Operating Expenses
$66.44MCash & Debt
$184.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $175.11M | $-221.25M | $-3.03 |
| 2024 | $55.25M | $-334.33M | $-5.29 |
| 2023 | $682.0K | $-201.59M | $-3.93 |
| 2022 | $0.00 | $-197.72M | $-5.70 |
| 2021 | $0.00 | $-143.88M | $-4.00 |
| 2020 | $0.00 | $-129.07M | $-4.01 |
| 2019 | $0.00 | $-209.74M | $-8.48 |
| 2018 | $0.00 | $-1.29M | $-0.15 |
Valuation
PHAThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+100.00%Social Signal Score
Mentions (13)
- Newsglobenewswire.com·3d ago·Positive
Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously Heartburn two or more times a week may be a sign of gastroesophageal reflux disease (GERD), which affects an estimated 65 million Americans A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
View source ↗ - Newsfool.com·4d ago·Neutral
Phathom: 3 Key Takeaways for Long-Term Investors Phathom reported third-quarter net revenues of $84.7 million. Commercially insured patients can access VOQUEZNA for a $0 copay through BlinkRx.
View source ↗ - Newszacks.com·16d ago·Positive
Implied Volatility Surging for Phathom Pharmaceuticals Stock Options Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Phathom Pharmaceuticals to Participate in November Investor Conferences FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA Date: Tuesday, N…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx A Media Snippet accompanying this announcement is available by clicking on this link.
View source ↗ - Newsmarketbeat.com·24d ago·Positive
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company continued efforts to expand access to its GERD treatment VOQUEZNA.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·24d ago·Neutral
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates Phathom Pharmaceuticals, Inc. (PHAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.15 per share a year ago.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Phathom Pharmaceuticals Provides Update on FDA Litigation FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration's (FDA's) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a fi…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT
View source ↗ - Newsglobenewswire.com·45d ago·Positive
…cacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
…ch proton pump inhibitors (PPIs) are not currently approved in the U.S. FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA® (vonopra…
View source ↗ - Newsbusinesswire.com·67d ago·Negative
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.09 per share
Typical surprise -3.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$-0.16 vs $-0.11miss
- Thu, Jul 30$-0.21 vs $-0.18miss
- Thu, Apr 30$-0.37 vs $-0.27miss
- Thu, Feb 26$-0.29 vs $-0.32beat
- Thu, Oct 30$-0.41 vs $-0.40miss
- Thu, Aug 7$-0.79 vs $-0.76miss
Estimates and results for PHAT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHAT officers and directors.
- Bought
- $261k
- Sold
- $139k
9 trades
6 trades
- Breedlove Robert Charlessold
- Breedlove Robert Charlessold
- Breedlove Robert Charlessold
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
- Topper James Nbought
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PHAT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
